טוען...
Development of a CART Model to Predict the Synthesis of Cardiotoxic Daunorubicinol in Heart Tissue Samples from Donors with and without Down Syndrome
Daunorubicin (DAUN) and doxorubicin (DOX) are used to treat a variety of cancers. The use of DAUN and DOX is hampered by the development of cardiotoxicity. Clinical evidence suggests that patients with leukemia and Down syndrome (DS) are at increased risk for anthracycline-related cardiotoxicity. Ca...
שמור ב:
| הוצא לאור ב: | J Pharm Sci |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4885781/ https://ncbi.nlm.nih.gov/pubmed/27112290 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xphs.2016.03.013 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|